Skip to main content
Premium Trial:

Request an Annual Quote

Genome Therapeutics Promotes Kley to VP For Functional Genomics

Premium

WALTHAM, Mass.--Genome Therapeutics announced the promotion of Nikolai Kley to vice-president, functional genomics. Kley joined Genome Therapeutics in January 1997 from Bristol-Myers Squibb Pharmaceutical Research Institute. At Genome Therapeutics, Kley and his team have strengthened the firm's functional genomics capabilities, notably in signal pathway analysis, protein interaction networks in yeast and mammalian systems, expression cloning, and drug target validation, according to Robert Hennessey, the company's president. Kley will continue to oversee Genome Therapeutics' functional genomics programs, including exploration of signaling pathways for the p53 tumor suppressor gene to identify new pharmaceutical targets for cancer.

Filed under

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.